Pharmacogenomics
-
Upload
drsirisha -
Category
Health & Medicine
-
view
192 -
download
4
Transcript of Pharmacogenomics
![Page 1: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/1.jpg)
SIRISHA ANNAVARAPU
DEPT OF PHARMACOLOGY, KIMS
![Page 2: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/2.jpg)
Introduction
• Pharmacogenomics deals with the influence of
genetic variation on drug response by co-relating
gene expression or polymorphism with a drug’s
efficacy or toxicity
• It intends to identify individuals who are either more
likely or less likely to respond to a drug, as well as
those who require altered dose of certain drugs
![Page 3: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/3.jpg)
Introduction
• Pharmacogenetics is often a study of the variations
in a targeted gene, or group of functionally related
genes.
• Pharmacogenomics is the use of genetic information
to guide the choice of drug and dose on an individual
basis.
![Page 4: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/4.jpg)
Pharmacogenomics Pharmacogenetics Genetic toxicology
use of geneticinformation to guide the choice of drug and dose on an individual basis.
The study ofgenetic basis forvariability in drugResponse
Study of the effect of chemical or physical agents on the heredity material (DNA) and on the genetic process of living cells.
Differences
![Page 5: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/5.jpg)
NORMAL GENE SNP VARIANT GENE
TODAY’S DRUG
PHARMACOGENOMIC DRUG
Principle of Pharmacogenomics
![Page 6: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/6.jpg)
Potential of Pharmacogenomics
![Page 7: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/7.jpg)
GENETICS AND MUTATION
![Page 8: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/8.jpg)
Genotype• The genetic constitution of an individual.
Experimental evaluation of Genotype (Genotyping)
Collect blood (> 1 ml)
Isolate DNA from nucleated blood cells.
Amplify number of copies of DNA by the Polymerase
Chain Reaction (PCR).
Genotype by sequencing or probing.
![Page 9: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/9.jpg)
Genetic polymorphism / mutation
• Mutations are inheritable changes produced in the
genetic information stored in the DNA of living cells.
Mutation is a difference in DNA sequence among
individuals, groups, or populations. Sources include
SNPs, sequence repeats, insertions, deletions and
recombination.
![Page 10: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/10.jpg)
Single Nucleotide Polymorphism
(SNP)
• DNA sequence variation that occurs when a single
nucleotide in the genome sequence is altered.
…CTAGATACGAACTGCATC…
…CTAGATACGGACTGCATC…
![Page 11: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/11.jpg)
![Page 12: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/12.jpg)
Consequences of polymorphisms
• May result in a different amino acid or stop
codon
• May result in a change in protein function or
quantity
• No effect
![Page 13: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/13.jpg)
ADVANTAGES AND
DISADVANTAGES OF
PHARMACOGENOMICS
![Page 14: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/14.jpg)
Advantages of pharmacogenomics
![Page 15: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/15.jpg)
Barriers of pharmacogenomics
1. Complexity of finding gene variations that affect drug
response.
Millions of SNPs must be identified and analyzed to
determine their involvement (if any) in drug response.
Many genes are likely to influence responses
Limited knowledge of which genes are involved with
each drug response
Confidentiality, privacy and the use and storage of
genetic information
![Page 16: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/16.jpg)
Barriers of pharmacogenomics
2. Educating healthcare providers & patients
• Complicates the process of prescribing and
dispensing drugs
• Physicians must execute an extra diagnostic step to
determine which drug is best suited to each patient
• Need for a better understanding of genetics by all
physicians
![Page 17: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/17.jpg)
Barriers of pharmacogenomics
3. Disincentives for drug companies to make multiple
pharmacogenomic products
Most pharmaceutical companies have been successful
with their "one size fits all" approach to drug
development
For small market- Pharmaceutical companies has to
spend hundreds of millions of dollars on
pharmacogenomics based drug development
![Page 18: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/18.jpg)
Amphichip
• Determine the genotype of the patient in terms of two
CYPP450 enzymes: 2D6 and 2C19
• FDA approved the test on December 24, 2004. The
AmphiChip CYP450 test is the first FDA
approved pharmacogenetic test.
![Page 19: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/19.jpg)
PHARMACOGENOMICS IN
DRUG METABOLISM
![Page 20: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/20.jpg)
Role of genes in PK & PD
![Page 21: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/21.jpg)
Candidate genes for variable drug
response(1) Proteins involved in drug transport:
Drug transporters (e.g. ABC and SLC) show
considerable genetic variation including many
functional polymorphisms.
(2) Genes that code for drug-metabolizing enzymes
(DME): Most DME-encoding genes have
polymorphisms that have been shown to influence
enzymatic activity.
![Page 22: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/22.jpg)
Pharmacogenomics of drug
transporters
• PGP (MDR 1) serves as barrier against entry of
compounds into the body, as well as from entering
tissues
![Page 23: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/23.jpg)
OATP-C*5 and OATP-C*9 have reduced uptake of OATP-C substrates
High plasma levels of pravastatin
Increased toxicity and reduced efficacy
![Page 24: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/24.jpg)
Enzymes involved in drug
metabolism
![Page 25: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/25.jpg)
Effects of CYP variants on
therapeutic efficacy
![Page 26: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/26.jpg)
Examples of Genetic Polymorphisms
Influencing Drug Response GENE PRODUCT (GENE) RESPONSES AFFECTED
CYP2C9 Anticoagulant effect of
warfarin
CYP2C19 Peptic ulcer response to
omeprazole
CYP2D6 Tardive dyskinesia from
antipsychotics, narcotic side
effects, codeine efficacy,
imipramine dose requirement,
β blocker effect
![Page 27: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/27.jpg)
CYP2D6
![Page 28: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/28.jpg)
CYP 2C
• CYP2C9 * 2 and CYP2C9 * 3 variants are of
significance- PM
![Page 29: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/29.jpg)
Drugs whose safety and efficacy
are affected by gene variations
![Page 30: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/30.jpg)
Using pharmacogenomics to predict
and prevent adverse drug reactions • Abacavir:
• Patients who carry the HLA-B*5701 allele are at high
risk for experiencing a hypersensitivity reaction to
abacavir.
• Prior to initiating therapy with abacavir, screening for
the HLA-B*5701 allele is recommended; this
approach has been found to decrease the risk of a
hypersensitivity reaction.
![Page 31: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/31.jpg)
• Irinotican: Patients homozygous or heterozygous for
the UGT1A1*28 allele have elevated levels of SN-38
and consequently are susceptible to bone marrow and
gastrointestinal side effects
![Page 32: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/32.jpg)
Using pharmacogenomics to
predict effectiveness
• Clopidogrel:
• CYP2C19, mediates the conversion of clopidogrel
into the active metabolite. Patients who carry
variations in CYP2C19 are considered poor
metabolizers and show reduced ability to convert
clopidogrel into its active metabolite, resulting in a
diminished antiplatelet effect.
![Page 33: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/33.jpg)
![Page 34: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/34.jpg)
• Tamoxifen:
• ER+ breast cancer
• CYP2D6*4 --- Poor metabolizer(7-10%)- frequent
relapse , worse disease free survival
![Page 35: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/35.jpg)
Using pharmacogenomics to
predict optimal dose
• Warfarin:
• Warfarin has a narrow therapeutic index; variations in
CYP2C9 and VKORC1, make it difficult to predict
the effective dose. Those carrying certain CYP2C9
and VKORC1 variations are likely to require altered
doses and may require prolonged time to reach a
stable maintenance dose.
![Page 36: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/36.jpg)
![Page 37: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/37.jpg)
Targets and receptors
Angiotensin-converting
enzyme (ACE)
ACE inhibitors (e.g.,
enalapril)
Renoprotective effects,
hypotension, left
ventricular mass
reduction, cough
Thymidylate synthase Methotrexate Leukemia response,
colorectal cancer
response
β2 Adrenergic receptor β2 Antagonists (e.g.,
albuterol, terbutaline)
Bronchodilation,
Dopamine receptors Antipsychotics Antipsychotic
response (D2, D3, D4),
tardive dyskinesia
![Page 38: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/38.jpg)
PHARMACOGENOMICS IN
CLINICAL TRIALS
![Page 39: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/39.jpg)
Applying PGs
.
DISEASE GENETICS
TARGETVARIABILITY
SELECTINGRESPONDERS
PHARMACO-GENETICS
Discovery Development
Choosing
the Best
Targets
Better
Understandin
g of our
Targets
Improving
Early
Decision
Making
Predicting
Efficacy
and Safety
![Page 40: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/40.jpg)
Pharmacogenomics in various stages
of drug development• Drug target identification –identification and
characterization of gene coding for the drug target
and to assess the variability.
• Phase I II &III – patient selection, inclusion and
exclusion criteria, dose range selection, dose
modification ,interpretation of trial result based on
Pharmacogenetic test results.
• Phase IV analysis of reported adverse effects with
pharmacogenetic tests.
![Page 41: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/41.jpg)
![Page 42: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/42.jpg)
![Page 43: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/43.jpg)
References • Ellis KJ, Stouffer GA, McLeod HL, Lee CR.
Clopidogrel pharmacogenomics and risk of
inadequate platelet inhibition: U.S. FDA
recommendations. (2009). Pharmacogenomics
10(11):1799–1817.
• Collins FS. 2010. The Future of Personalized
Medicine. NIH Medline Plus 5(1):2–3.
• Belle DJ, Singh H. (2008). Genetic Factors in Drug
Metabolism. Am Fam Physician 77(11):1553–1560.
• Rollason V, Samer C, Piguet V, Dayer P, Desmeules
J. (2008). Pharmacogenomics of analgesics: Toward
the individualization or prescription.
Pharmacogenomics 9(7):905–933.
![Page 44: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/44.jpg)
• Mallal S, Phillips E, Carosi G, Molina JM, Workman
C, Tomazic J et al. (2008). HLA-B*5701 screening
for hypersensitivity to abacavir. N Engl J Med
358(6):568–579.
• Willmann S, Edginton AN, Coboeken K, Ahr A,
Lippert J. (2009). Risk to the Breast-Fed
NeonateFrom Codeine Treatment to the Mother: A
Quantitative Mechanistic Modeling Study. Clin
Pharmacol Ther 86(6):634–643.
• Ingelman-Sundberg M, Sim SC, Gomez
A,Rodriguez-Antona C. (2007). Influence of
cytochrome P450 polymorphisms on drug
therapies:Pharmacogeneic, pharmacoepigenetic, and
clinical aspects. Clin Pharmacol Ther 116:496–526.
![Page 45: Pharmacogenomics](https://reader033.fdocuments.in/reader033/viewer/2022042701/55a5e2c91a28ab3c368b4615/html5/thumbnails/45.jpg)
THANK YOU